It is with great pride that I reflect on 2024, a truly transformative year for Immedica. This transformation has positioned us to take significant steps toward realizing our vision of becoming a global leader in delivering innovative rare disease products to patients with significant need of improved treatments. Below, I would like to highlight some of the key milestones that have defined this remarkable year.
One pivotal milestone was the restructuring of our ownership, with KKR and Impilo AB now backing Immedica. This provides the support and resources to accelerate our search for innovative rare disease products—both those with existing sales and those approaching regulatory approval. While our growth prospects are already strong, a steady pipeline of new products will drive even greater success in the years ahead.
Another transformative event was the establishment of our commercial hub in Chicago, U.S. This marks our strategic expansion into the world’s largest pharmaceutical market. The move ensures that we are well-positioned to commercialize Loargys and other rare disease treatments not only across Europe and MENA but also in the United States, strengthening our global presence.
A major highlight of 2024 was the launch of Loargys in Europe and MENA. For the first time, Immedica has introduced its own proprietary product—one we successfully guided through the regulatory process across these regions. Bringing Loargys to market involved extensive planning and execution across medical education, manufacturing, supply chain, pricing, market access, and regulatory management. I am incredibly proud of the collective effort that has made Loargys accessible to children with ARG1-D.
Our transformative journey continued with the signing of an agreement to acquire Marinus Pharmaceuticals, headquartered in the U.S. Marinus brings global rights to Ztalmy, an orphan drug for difficult-to-treat hereditary pediatric epilepsy. This acquisition not only introduces our first product to the U.S. market, with strong and growing sales, but also provides an established U.S organization to support Loargys once regulatory approval is achieved, hopefully by mid-2025.
In addition to these transformative events, we have strengthened our focus on ESG initiatives. Our core mission—to deliver life-changing treatments to people with rare diseases—forms the foundation of our ESG efforts. Complementing this, we have advanced initiatives in Diversity, Equity, and Inclusion (DEI) to continue to foster a sustainable and inclusive corporate culture. At Immedica, ESG is not a separate layer but an integrated part of our operations, ensuring it remains authentic and impactful.
Our culture remains a cornerstone of our success. It unites our teams, enabling cross-functional projects to run with quality, speed, and cost-effectiveness. This year, we were proud to be recognized as a Great Place to Work for the second consecutive year. In the beginning of 2024, we were Sweden’s top-ranked life sciences company in Sweden´s best workplaces based on the results we achieved in 2023. In 2024, our scores improved even further.
Looking ahead to 2025, we anticipate these transformative milestones will continue to shape our business and, more importantly, improve the lives of people with rare diseases worldwide. By the end of 2025, we aspire to have two proprietary, growing orphan products in full launch in the U.S.—an achievement that would have been unimaginable just a few years ago.
None of this would be possible without the dedication of our team, the trust of our partners, and the resilience of the rare disease community. Together, we have achieved extraordinary results. As we step into 2025, our commitment to improving lives through innovative rare disease treatments has never been stronger.
Anders Edvell
Chief Executive Officer
